학술논문

Rivastigmine Lowers A&bgr; and Increases sAPP&agr; Levels, Which Parallel Elevated Synaptic Markers and Metabolic Activity in Degenerating Primary Rat Neurons.
Document Type
Article
Source
PLoS ONE. 2011, Vol. 6 Issue 7, p1-12. 12p.
Subject
*ALZHEIMER'S disease treatment
*NEUROPLASTICITY
*BIOMARKERS
*AMYLOID beta-protein
*BRAIN function localization
*MILD cognitive impairment
*CELL metabolism
*LABORATORY rats
Language
ISSN
1932-6203
Abstract
Overproduction of amyloid-&bgr; (A&bgr;) protein in the brain has been hypothesized as the primary toxic insult that, via numerous mechanisms, produces cognitive deficits in Alzheimer's disease (AD). Cholinesterase inhibition is a primary strategy for treatment of AD, and specific compounds of this class have previously been demonstrated to influence Ab precursor protein (APP) processing and A&bgr; production. However, little information is available on the effects of rivastigmine, a dual acetylcholinesterase and butyrylcholinesterase inhibitor, on APP processing. As this drug is currently used to treat AD, characterization of its various activities is important to optimize its clinical utility. We have previously shown that rivastigmine can preserve or enhance neuronal and synaptic terminal markers in degenerating primary embryonic cerebrocortical cultures. Given previous reports on the effects of APP and A&bgr; on synapses, regulation of APP processing represents a plausible mechanism for the synaptic effects of rivastigmine. To test this hypothesis, we treated degenerating primary cultures with rivastigmine and measured secreted APP (sAPP) and A&bgr;. Rivastigmine treatment increased metabolic activity in these cultured cells, and elevated APP secretion. Analysis of the two major forms of APP secreted by these cultures, attributed to neurons or glia based on molecular weight showed that rivastigmine treatment significantly increased neuronal relative to glial secreted APP. Furthermore, rivastigmine treatment increased a-secretase cleaved sAPPa and decreased Ab secretion, suggesting a therapeutic mechanism wherein rivastigmine alters the relative activities of the secretase pathways. Assessment of sAPP levels in rodent CSF following once daily rivastigmine administration for 21 days confirmed that elevated levels of APP in cell culture translated in vivo. Taken together, rivastigmine treatment enhances neuronal sAPP and shifts APP processing toward the &agr;-secretase pathway in degenerating neuronal cultures, which mirrors the trend of synaptic proteins, and metabolic activity. [ABSTRACT FROM AUTHOR]